Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.
Department of Oncology and Hematology, Ospedali Riuniti Marche Nord, 61121 Pesaro, Italy.
Int J Mol Sci. 2017 Nov 9;18(11):2382. doi: 10.3390/ijms18112382.
Pelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25% of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic perfusion may, therefore, be an option for these non-responsive patients. Overall median survival time (MST), stratified for variables, including BRAF V600E mutation and eligibility for treatments with new immunotherapy drugs, was retrospectively assessed in 41 patients with pelvic melanoma loco regional metastases. They had received a total of 175 treatments with Melphalan hypoxic perfusion and cytoreductive excision. Among the 41 patients, 22 (53.7%) patients exhibited a wild-type genotype, 11 of which were not eligible for immunotherapy. The first treatment resulted in a 97.5% response-rate in the full cohort and a 100% response-rate in the 22 wild-type patients. MST was 18 months in the full sample, 20 months for the 22 wild-type patients and 21 months for the 11 wild-type patients not eligible for immunotherapy. Melphalan hypoxic perfusion is a potentially effective treatment for patients with pelvic melanoma loco regional metastases that requires confirmation in a larger multicenter study.
盆腔黑色素瘤局部转移患者中有 15%会出现复发，25%的病例对新的靶向治疗和/或免疫治疗无反应。因此，对于这些无反应的患者，低氧盆腔灌注美法仑可能是一种选择。对 41 例盆腔黑色素瘤局部转移患者的总生存时间（MST）进行回顾性评估，这些患者按 BRAF V600E 突变和新免疫治疗药物治疗的资格等变量分层。他们共接受了 175 次美法仑低氧灌注和细胞减灭切除术治疗。在这 41 名患者中，22 名（53.7%）患者表现出野生型基因型，其中 11 名患者不符合免疫治疗条件。在全队列中，首次治疗的反应率为 97.5%，在 22 名野生型患者中为 100%。全样本的 MST 为 18 个月，22 名野生型患者的 MST 为 20 个月，11 名不符合免疫治疗条件的野生型患者的 MST 为 21 个月。低氧盆腔灌注美法仑可能是治疗盆腔黑色素瘤局部转移的一种有效方法，需要在更大的多中心研究中得到证实。
